CEDARHURST, NY / ACCESSWIRE / August 27, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

International Flavors & Fragrances Inc. (NYSE:IFF)

Investors Affected : May 7, 2018 – August 5, 2019

A class action has commenced on behalf of certain shareholders in International Flavors & Fragrances Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) that Frutarom Industries Ltd. (“Frutarom”), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom’s financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/international-flavors-fragrances-inc-loss-submission-form/?id=3217&from=1

2U, Inc. (NASDAQGS:TWOU)

Investors Affected : February 26, 2018 – July 30, 2019

A class action has commenced on behalf of certain shareholders in 2U, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) 2U’s business model was fundamentally flawed because the Company’s costs were growing disproportionately as it grew in size and complexity; (b) 2U could not take advantage of the promised economies of scale because its costs to attract each marginal student were actually increasing, not decreasing, as represented; (c) 2U was facing heightened competitive headwinds as alternative offerings flooded the marketplace and universities developed online courses in-house; (d) 2U’s growth rate in student enrollment was decelerating and was poised to decline as the Company reached market saturation; (e) 2U’s growth strategy was unsustainable, as the Company faced accelerating costs and had insufficient capital to achieve positive cash flows, improve margins or continue its revenue growth; and (f) as a result of (a)-(e), above, Defendants lacked any reasonable basis to issue 2U’s projections and financial forecasts.

Shareholders may find more information at https://kclasslaw.com/securities/2u-inc-loss-submission-form/?id=3217&from=1

NetApp, Inc. (NASDAQGS:NTAP)

Investors Affected : May 22, 2019 – August 1, 2019

A class action has commenced on behalf of certain shareholders in NetApp, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was unable to close large deals within the quarter and that the deals were pushed out to subsequent quarters or downsized; (2) as a result, the Company’s revenue would be materially impacted; (3) as a result, the Company would lower its fiscal 2020 guidance; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/netapp-inc-loss-submission-form/?id=3217&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC

ReleaseID: 557685

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 19, 2019, Sarepta announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food & Drug Administration regarding the Company’s New Drug Application seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy. Sarepta disclosed that “[t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides.” On this news, Sarepta’s stock price fell sharply, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 557675

HOUSTON, TX / ACCESSWIRE / August 27, 2019 / Spark Energy, Inc. (“Spark” or the “Company”) (NASDAQ:SPKE), an independent retail energy services company, announced today that Amanda (Mandy) Bush has been appointed to the Company’s Board of Directors, effective August 27, 2019, as an independent director. She will serve as a Class III director, and will join the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. She will also serve as Chair of the Audit Committee.

“We are very pleased to welcome Mandy to our board and look forward to her contributions,” said Nathan Kroeker, Spark’s President and Chief Executive Officer. “Mandy brings extensive corporate experience and in-depth accounting knowledge that will complement the work and expertise of our other directors as well as fulfill all NASDAQ listing requirements as Spark’s third independent director. We are confident she will make an immediate and meaningful contribution to the work of our Board of Directors, and we look forward to her participation as we continue to execute our growth strategy. Additionally, we are pleased to introduce our first female director to the Board since our IPO in August 2014, furthering our commitment to diversity.”

“I’m honored to join Spark’s board and I look forward to the opportunity to help guide the Company as it continues to deliver on the promise of stable earnings growth,” said Ms. Bush. “It’s exciting to be working with Spark in this pivotal time in the retail energy industry.”

As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2019, James G. Jones II resigned from the Board of the Company effective June 13, 2019 to serve as Chief Financial Officer of the Company, resulting in the Audit Committee of the Board consisting of only two independent directors. The Company received a notification from the NASDAQ Global Select Market (“NASDAQ”) on June 17, 2019 that it did not satisfy NASDAQ Listing Rule 5605(c)(2)(A), which requires the Company’s Audit Committee to consist of at least three independent directors. The Company believes that the appointment of Ms. Bush as an independent director to serve as the third member of the Audit Committee will allow the Company to regain compliance with NASDAQ Listing Rule 5605(c)(2)(A).

About Mandy Bush

Mandy Bush is the Chief Financial Officer of Azure Midstream Energy, LLC. Prior to joining Azure, she was the Chief Financial Officer at Marlin Midstream Partners, LP, leading their successful IPO in 2013. Prior to being the CFO of Marlin, Ms. Bush held various finance and accounting roles within the energy industry. Ms. Bush began her career in public accounting with PwC auditing Fortune 500 companies. She has a master’s degree in accounting from the University of Houston and is a Texas certified public accountant.

About Spark Energy, Inc.

Spark Energy, Inc. is an independent retail energy services company founded in 1999 that provides residential and commercial customers in competitive markets across the United States with an alternative choice for their natural gas and electricity. Headquartered in Houston, Texas, Spark currently operates in 19 states and serves 94 utility territories. Spark offers its customers a variety of product and service choices, including stable and predictable energy costs and green product alternatives.

We use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should note that new materials, including press releases, updated investor presentations, and financial and other filings with the Securities and Exchange Commission are posted on the Spark Energy Investor Relations website at ir.sparkenergy.com. Investors are urged to monitor our website regularly for information and updates about the Company.

Cautionary Note Regarding Forward Looking Statements

This release contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. These forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) can be identified by the use of forward-looking terminology including “may,” “should,” “likely,” “will,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “plan,” “intend,” “project,” or other similar words. Forward-looking statements appear in this press release and include statements about our ability to regain compliance with the standards of NASDAQ. The forward-looking statements in this press release are subject to risks and uncertainties. Important factors that could cause actual results to materially differ from those projected in the forward-looking statements include, but are not limited to the “Risk Factors” in our latest Annual Report on Form 10-K for the year ended December 31, 2018, in our Quarterly Reports on Form 10-Q, and other public filings and press releases.

You should review the risk factors and other factors noted throughout this press release. All forward-looking statements speak only as of the date of this press release. Unless required by law, we disclaim any obligation to publicly update or revise these statements whether as a result of new information, future events or otherwise. It is not possible for us to predict all risks, nor can we assess the impact of all factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Contact: Spark Energy, Inc.

Investors:
Christian Hettick, 832-200-3727

Media:
Kira Jordan, 832-255-7302

SOURCE: Spark Energy, Inc.

ReleaseID: 557671

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Karyopharm Therapeutics Inc (NASDAQGS:KPTI)

Investors Affected: on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.

A class action has commenced on behalf of certain shareholders in Karyopharm Therapeutics Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

Shareholders may find more information at https://securitiesclasslaw.com/securities/karyopharm-therapeutics-inc-loss-submission-form/?id=3216&from=1

Just Energy Group Inc. (NYSE:JE)

Investors Affected: November 9, 2017 – July 23, 2019

A class action has commenced on behalf of certain shareholders in Just Energy Group Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company experienced customer enrollment and nonpayment issues; (2) as a result, the Company was reasonably likely to incur an impairment charge to its accounts receivable; (3) as a result, the Company lacked adequate internal control over its financial reporting; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/just-energy-group-inc-loss-submission-form/?id=3216&from=1

GTT Communications, Inc. (NYSE:GTT)

Investors Affected: February 26, 2018 – July 1, 2019

A class action has commenced on behalf of certain shareholders in GTT Communications, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) following GTT’s acquisition of Interoute Communications Holdings S.A., there were delays in migrating Interoute’s legacy systems and processes into GTT’s client management database system; (2) Interoute had made a strategic priority shift to sell cloud services that was a higher percentage of Interoute’s sales in the two years leading up to the acquisition; (3) a material percentage of the Interoute sales representatives were not productive at selling GTT’s core cloud networking services; (4) GTT was unable to yield as many Interoute salespeople because Interoute had hired many sales people focused on cloud services and allowed underperforming sales representatives to remain at Interoute; and (5) as a result of the foregoing, Defendants’ public statements were materially false and/or misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/gtt-communications-inc-loss-submission-form/?id=3216&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 557677

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Textron, Inc. (“Textron” or the “Company”) (NYSE:TXT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Textron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 18, 2018, Textron reported weak third quarter 2018 earnings and cut its full-year 2018 forecast. Textron blamed the shortfall on heavy discounts issued by Textron to clear out old inventory. Analysts immediately lowered their price targets on Textron stock, citing inventory concerns at the Company’s Arctic Cat Inc. subsidiary.

On this news, Textron’s stock price fell $7.29 per share, or 11.25%, to close at $57.49 per share on October 18, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 557672

DENVER, CO / ACCESSWIRE / August 27, 2019 / Franklin D. Azar & Associates, P.C. announces that a lawsuit has been filed on behalf of shareholders of Cardinal Health, Inc. (NYSE:CAH). Investors who purchased CAH securities between March 2, 2015 and May 2, 2018, and are interested in learning about the case or serving as a lead plaintiff, are encouraged to visit our website to submit your information and learn more about the case. The lawsuit alleges that Cardinal Health violated the federal securities laws.

The lawsuit alleges that the Defendants made materially false and misleading statements and omissions relating to Cardinal’s integration of Cordis Corp. (“Cordis”), a medical device manufacturer Cardinal purchased from Johnson & Johnson (“J&J”) in March 2015, and inventory and supply chain problems at Cordis.

If you purchased Cardinal Health securities (NYSE:CAH) between March 2, 2015 and May 2, 2018 and are interested in the lead plaintiff process, please contact the Azar Law Firm’s shareholder rights team at www.fdazar.com. Investors may also contact the firm via email at securities@fdazar.com, or calling 844-241-9475. Interested shareholders have until September 30, 2019 to apply to be lead plaintiff. The class has not yet been certified. Until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Azar Law Firm’s securities attorneys are highly experienced in representing individual shareholders and institutional investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of shareholders. Azar Law Firm is working with Thornton Law LLP in investigating this action. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Ivy T. Ngo
Franklin D. Azar & Associates, P.C.
14426 East Evans Ave
Aurora, CO 80014
Email: ngoi@fdazar.com
Tel: 303-757-3300

SOURCE: Franklin D. Azar and Associates P.C.

ReleaseID: 557669

Over decades of personalized care and attention, Dr. Muhammed Niaz has helped countless patients live their healthiest lives by providing industry-leading medical solutions. Practicing internal medicine, he is able to help prevent, diagnose, and treat diseases that affect his adult patients.

NEWARK, DE / ACCESSWIRE / August 27, 2019 / Dr. Muhammed Niaz MD is dedicated to quality care to his patients in the Delaware area, and provides them many resources to help take control of their health and prevent major illnesses. As an internal medicine specialist, Dr. Niaz creates meaningful relationships with his patients and oversees their general care in addition to studying factors like genetics and family illnesses to ward off disease in the future.

One of the biggest concerns Dr. Muhammed Niaz MD comes across is poor heart health, or the potential for poor heart health due to patients’ eating habits and lack of physical activity.

“Poor heart health is one of the most detrimental illnesses facing people in America right now,” says Muhammed Niaz MD. “A staggering number of citizens–some estimates claim as much as half of the population–live with some sort of cardiovascular disease or heart health concerns. It’s as much of a threat, if not wildly more so, than illnesses like Alzheimer’s or cancer.”

One of the milestones of a credible internal medicine specialist is the ability to offer non-medical solutions in addition to any tests or procedures for improved health. This includes things like improved diet plans, new exercise routines or physical fitness, and better sleeping schedules among other useful components.

“All patients can benefit from a few simple lifestyle changes that will ensure they’re treating their bodies appropriately and can age without worry of major illnesses or disease,” says Dr. Muhammed Niaz MD.

Above all, he asks that his patients find a physical activity they love and can participate in a few times a week. In lieu of a sport like soccer or hobby like kayaking, he advises taking short walks around the neighborhood to increase heart rate and warm up the body’s various systems. Weight management is a big factor in positive health, and a brisk walk around the neighborhood each day is enough to get the metabolism going to burn off fat and impurities.

Dr. Muhammed Niaz MD also suggests eating heart healthy foods and cutting out fatty or fried meals as often as possible. In its place, he advises incorporating more Omega 3 dietary fats and monounsaturated fats while avoiding trans and saturated fats altogether. Dr. Niaz also suggests adding vegetables and fruits rich in antioxidants to patients’ diets as well as foods like oatmeal that can help lower cholesterol.

“Achieving and maintaining optimal health is about lifestyle choices and everyday habits like regular activity and better foods,” says Dr. Muhammed Niaz MD. “Truthfully, it doesn’t take a lot of work for patients to fortify their bodies against common illnesses as they age.”

CONTACT:

Caroline Hunter
Web Presence, LLC
+1 7862338220

SOURCE: Web Presence

ReleaseID: 557659

VANCOUVER, BC / ACCESSWIRE / August 27, 2019 / Commerce Resources Corp. (TSXV:CCE)(FSE:D7H) (the “Company” or “Commerce”) is pleased to announce a non-brokered private placement consisting of the issuance of up to 11,538,461 units (each, a “Unit”) at a price of $0.26 per Unit for gross proceeds of up to $3,000,000 (the “Offering”). Existing shareholders will be given priority, within the available exemptions.

Insiders may participate in the Offering.

Each Unit will consist of one common share of the Company (each, a “Share”) and one common share purchase warrant (each, a “Warrant”), with each Warrant entitling the holder to purchase one Share at a price of $0.35 per Share for the first year, and $0.50 for the second year following the closing of the Offering (the “Closing”).

Finders’ fees may be payable in connection with the Offering in accordance with the policies of the TSX Venture Exchange (the “Exchange”).

All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after closing of the Offering. Completion of the Offering is subject to the approval of the Exchange. Any participation by insiders in the Offering will constitute a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) but is expected to be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101.

The aggregate gross proceeds from the sale of the Offering will be used to advance the developments of the Company’s Ashram REE Deposit in Quebec.

The Company has granted an aggregate of 1,505,000 stock options to certain directors, officers, employees and consultants of the Company for the purchase of up to 1,505,000 common shares of the Company pursuant to its Stock Option Plan. Each option is exercisable for a period of 5 years at a price of $0.35 per common share.

About Commerce Resources Corp.

Commerce Resources Corp. is an exploration and development company with a particular focus on deposits of rare metals and rare earth elements. The Company is focused on the development of its Ashram Rare Earth Element Deposit in Quebec and the Upper Fir Tantalum-Niobium Deposit in British Columbia.

For more information, please visit the corporate website at www.commerceresources.com or email info@commerceresources.com.

On Behalf of the Board of Directors
COMMERCE RESOURCES CORP.

“Chris Grove”
Chris Grove
President and Director
Tel: 604.484.2700
Email: cgrove@commerceresources.com
Web: http://www.commerceresources.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the proposed Offering, the expectations of management regarding the use of proceeds of the Offering, closing conditions for the Offering, the expiry of hold periods for securities distributed pursuant to the Offering, and Exchange approval of the proposed Offering. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that: the Company may not complete the Offering on terms favorable to the Company or at all; the Exchange may not approve the Offering; the proceeds of the Offering may not be used as stated in this news release; the funds raised from the sale of the Units may not be renounced in favour of the Unit holders; the Company may be unable to satisfy all of the conditions to the Closing; and those additional risks set out in the Company’s public documents filed on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE: Commerce Resources Corp.

ReleaseID: 557674

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / Pomerantz LLP is investigating claims on behalf of investors of International Flavors & Fragrances Inc. (“International Flavors” or the “Company”) (NYSE:IFF). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether International Flavors and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 5, 2019, IFF announced its financial results for the second quarter of 2019. IFF significantly lowered its 2019 guidance, advising investors that it expects adjusted earnings per share (“EPS”) of $4.85 to $5.05 on revenue of $5.15 billion to $5.25 billion, down from its previous guidance of adjusted EPS in the range of $4.90 to $5.10 and revenue of $5.2 billion to $5.3 billion. In addition, IFF disclosed that it is investigating improper payments made by two businesses of its Israeli subsidiary Frutarom “operating principally in Russia and Ukraine . . . to representatives of a number of customers.”

On this news, IFF’s stock price fell $22.56 per share, or 15.95%, to close at $118.91 per share on August 6, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 557665

NEW YORK, NY / ACCESSWIRE / August 27, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

3M Company (NYSE:MMM)
Class Period: February 9, 2017 to May 28, 2019
Lead Plaintiff Deadline: September 27, 2019

The lawsuit alleges that 3M Company made materially false and/or misleading statements and/or failed to disclose that: (i) 3M had vast internal evidence dating back decades confirming that polyfluoroalkyl substances (“PFAS”) are toxic (which was first publicly revealed in February 2018 by Minnesota’s Attorney General); (ii) 3M had a decades-long history of suppressing negative information and/or damaging data about PFAS; and (iii) 3M has legal exposure to state, county, and local governments and individuals around the country as a result of its knowledge and intentional concealment of the toxic harm caused by the use of PFAS.

Learn about your recoverable losses in MMM: http://www.kleinstocklaw.com/pslra-1/3m-company-loss-submission-form?id=3215&from=1

Reckitt Benckiser Group plc (OTCMKTS:RBGLY)
Class Period: On behalf of all purchasers of Reckitt American Depositary Shares (“ADSs”) from July 28, 2014 through April 9, 2019
Lead Plaintiff Deadline: September 13, 2019

During the class period, Reckitt Benckiser Group plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) defendants had engaged in a scheme to artificially inflate the sales of Suboxone Film by more than $3 billion by falsely touting the drug’s purportedly superior efficacy and safety as compared to tablets; (b) contrary to defendants’ public statements, the FDA and internal Company documents had concluded that Suboxone Film posed a potentially greater risk of abuse and child endangerment than other available treatments; (c) defendants had fabricated a safety scare involving Suboxone Tablets in order to unlawfully delay and prevent generic competition; (d) defendants had engaged in a massive marketing campaign that had misrepresented the purported benefits of Suboxone Film as compared to Suboxone Tablets to doctors, healthcare providers, government regulators and investors; (e) defendants had encouraged Suboxone sales through medical providers that they knew were overprescribing the drug, facilitating the drug’s abuse and/or prescribing it in a careless and clinically unwarranted manner, often to hundreds of individuals at a time; (f) as a result of (a)-(e) above, Reckitt’s revenues, net income an d earnings were artificially inflated and the product of illicit business practices; and (g) as a result of (a)-(f) above, Reckitt and Reckitt Pharma were exposed to extraordinary undisclosed legal and reputational risks that could result in billions of dollars in fines, lost business and legal judgments or other monetary penalties.

Learn about your recoverable losses in RBGLY: http://www.kleinstocklaw.com/pslra-1/reckitt-benckiser-group-plc-loss-submission-form?id=3215&from=1

L Brands, Inc. (NYSE:LB)
Class Period: May 31, 2018 to November 19, 2018
Lead Plaintiff Deadline: September 23, 2019

The complaint alleges L Brands, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the Victoria’s Secret and PINK businesses were having a material adverse effect on the Company’s cash flow, liquidity and debt levels; (b) Defendants lacked a reasonable basis for their positive statements about the ability of the Company to sustain its dividend; (c) the MD&A disclosures in filings L Brands made with the SEC were materially false and misleading; (d) the risk factor disclosures in filings L Brands made with the SEC were materially false and misleading; (e) the representations about L Brands’ disclosure controls in filings the Company made with the SEC were materially false and misleading; (f) the certifications issued by Defendants Wexner and Burgdoerfer on L Brands disclosure controls were materially false and misleading; and (g) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about L Brands’ then-current business operations and future financial
prospects.

Learn about your recoverable losses in LB: http://www.kleinstocklaw.com/pslra-1/l-brands-inc-loss-submission-form?id=3215&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 557662